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Abstract 
 Cocaine addiction is a brain disorder that negatively affects the lives of millions of people 
and causes great societal harm.  Most people who try cocaine do not become addicted to it.  
What predisposes someone to develop a cocaine dependency while others are able to control use 
is not well understood.  This study’s aim is to use a novel rat model of dopamine D2 autoreceptor 
sensitivity to assess addiction vulnerability.  We have found that rats with a high D2 autoreceptor 
sensitivity (PreHD2) are more sensitive to both the rewarding and psychomotor stimulating 
effects of cocaine than rats with a low D2 autoreceptor sensitivity.  We have found several 
neurobiological alterations within the nigrostriatal pathway, a region intimately involved in the 
motor behaviors of drugs of abuse that correlate with this differential behavioral profile.  We 
found that PreHD2 rats had decreased expression of adenosine A2A receptor, D2 receptor, 
Dopamine Transporter, and DARPP-32 within the Caudate Putamen, and decreased expression 
of Dopamine Transporter and Tyrosine Hydroxylase within the Substantia Nigra.  We also found 
differential activity-dependent phosphorylation of several phosphoproteins (pTH
Ser40
 and 
pDARPP-32
Thr34
) between PreHD2 and PreLD2 animals within the nigrostriatal pathway. 
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Introduction 
 Cocaine addiction is a brain disorder that causes thousands of deaths, millions in dollars 
of damage, and untold harm to the lives of addicts and their friends and families every year.  
According to the 2009-2010 National Survey on Drug Use and Health in the United States, 1.9% 
of the population had used cocaine in the past year.  However, of the people who have tried 
cocaine, only 15-16% will develop cocaine dependence within 10 years of first use (Wagner and 
Anthony, 2002).  The discrepancy between those who use and those who abuse cocaine may be 
explained through individual differences.  Though there are other contributing factors to drug 
dependence such as drug availability and social pressure, there are also pre-existing alterations 
within the neurobiology of individuals that predispose them to develop addiction (Piazza et. al, 
1996).   
 Though individual differences have been the focus of much study, it remains unclear 
what precisely confers resistance or vulnerability to addiction.  Some personality traits appear to 
increase the likelihood of developing substance dependence.  “Sensation seekers” are defined as 
people who have a desire for novel experiences, particularly novel hedonic experiences 
(Zuckerman, 1979).  Individuals who score highly on Zuckerman’s Sensation Seeking Scale 
(Zukerman, 1994) have been found to experience increased sensitivity to the reinforcing effects 
of psychostimulants (Leyton et. al, 2002). Sensation seekers also reported that they felt more 
stimulated by amphetamine, had greater drug liking, and also had higher break-points on 
progressive ratio responding relative to those who scored low on the sensation seeking scale 
(Hutchison et. al, 1999; Kelly et. al, 2006; Sax and Strakowski, 1998; Stoops et. al, 2007).  There 
is great interest in determining whether sensation seekers have neurobiological alterations within 
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the dopamine system that might account for these differential behavioral responses to 
psychostimulants.    
Psychostimulants like cocaine, amphetamine, methamphetamine, and methylphenidate 
share a common mechanism of action on monoamine transporters, especially the Dopamine 
Transporter (DAT).  These drugs all either block or reverse DAT and prevent dopamine re-
uptake into the presynaptic neuron, causing a flood of dopamine within the synapse.  Although 
certainly not the only neurotransmitter system involved in addiction, dopamine appears to be 
crucial in the development and maintenance of addiction (Koob and Volkow, 2010).  Therefore, 
it has been the primary focus of study on neurobiological alterations that confer vulnerability or 
resistance to addiction.  A positive correlation has been established between sensation seeking 
and dopamine release in the ventral striatum following treatment with amphetamine (Leyton et. 
al, 2002).  Genetic studies have found that both novelty seeking and methamphetamine 
dependence are correlated with a higher prevalence of the A1 allele of the dopamine D2 receptor, 
that is a lower functioning variant (Han et. al, 2008).  Additionally, people with lower levels of 
D2 receptor have reported greater drug liking for methylphenidate (Volkow et. al, 1999).  The D2 
receptor is coupled to a Gi/o protein and inhibits adenylyl cyclase, cyclic adenosine 
monophosphate (cAMP) formation, and PKA activity (Sibley et. al, 1993).  Additionally, it is 
frequently located presynaptically as an inhibitory autoreceptor (Mercuri et. al, 1997).  Given the 
D2 receptor’s synaptic localization, it has a powerful ability to inhibit dopamine release.  The 
decreased expression of presynaptic dopamine D2, or the expression of lesser functioning 
variants, could lead to heightened dopamine tone due to less inhibition, perhaps predisposing 
individuals to addiction. 
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 Due to ethical limitations in conducting human research, animal models have been very 
useful in elucidating how individual differences influence the development of addiction.  When 
rats are and allowed to self-administer a sub-threshold dosage of cocaine, some animals will 
develop a stable self-administration pattern, while others will not (Marinelli and White, 2000).  
This illustrates that, like humans, there exist individual variations within rats that induce a 
proclivity for drug dependence.  Several rodent animal models mirroring addiction vulnerability 
have been developed.  One such model is the so-called high responder (HR) rat, defined as an 
animal that has a high locomotor response to a novel environment (Piazza et. al, 1989).  HR rats 
not only find cocaine more reinforcing (as evidenced by increased operant responding and 
establishment of stable self-administration at lower doses, for longer periods of time) they have 
been found to have several alterations in their midbrain dopaminergic signaling (Marinelli and 
White, 2000; Piazza et al., 2000; Blanchard et al., 2009).  Specifically, they were found to have 
increased firing rates compared to low responder rats (LR) in the ventral tegmental area and the 
substantia nigra (Marinelli and White, 2000).  Similar to human sensation seekers, HR rats also 
had decreased levels of D2 receptors in the striatum (Hooks et. al, 1994).  The aim of this present 
study is to use a novel animal model where individual differences in D2 autoreceptor sensitivity 
are used assess both differential behavioral responses to cocaine as well as neurobiological 
alterations within the midbrain dopamine systems. 
Preliminary Findings and Predictions 
 Cocaine exposure has been found to induce behavioral alterations in a number of 
different paradigms.  Of interest to this study is cocaine’s ability to induce locomotor activity.  
This effect has been found to be D2 receptor dependent, as the D2 agonist quinpirole has also 
been demonstrated to induce locomotor activation, and repeated cocaine administration produces 
Schreiner 7 
 
cross-sensitization to D2 receptor stimulation (Ujike et al., 1990; De Vries et al., 2002).  
Interestingly, rats display large amounts of variability in locomotor patterns following D2 
receptor stimulation.   We utilized these individual differences in their locomotor response to an 
initial, low (0.1mg/kg) dosage of quinpirole as a model to test D2 receptor sensitivity as a 
vulnerability factor.  Low doses of quinpirole (i.e. 0.1 mg/kg) are thought to selectively target the 
higher affinity D2 autoreceptors (Jeziorski and White, 1989).  Behaviorally, these low, 
autoreceptor selective doses inhibit locomotor activity due to the stimulation of the autoreceptors 
and suppression of dopamine release.  Subsequent escalating doses (i.e. 0.3mg/kg and 1.0mg/kg) 
tend to induce locomotor activation through the stimulation of the lower affinity postsynaptic D2 
receptors throughout the striatum.  We found that some rats displayed a robust suppression of 
locomotor activity to the autoreceptor selective dose, while others saw minimal suppression or 
even activation.  Those animals who displayed a robust suppression were characterized as having 
high expression and/or sensitivity of their presynaptic D2 autoreceptors (PreHD2), while those 
with minimal suppression or activation were characterized as having low levels and/or low 
sensitivity of their presynaptic D2 autoreceptors (PreLD2).  Animals were placed into these 
respective groups via a median split of their locomotor response to 0.1mg/kg of quinpirole. This 
novel model of D2 autoreceptor sensitivity provided us with an interesting tool to both examine 
individual differences in behavioral responses to cocaine and explore neurobiological correlates 
within the nigrostriatal dopamine pathway. 
We first sought to determine what effects the heightened sensitivity of the D2 
autoreceptors would have on behavioral measures of cocaine sensitivity.  In one cohort of 
animals, we assessed their locomotor response to cocaine.  We found that the PreHD2 animals 
displayed an increased locomotor response relative to PreLD2 animals.  In another cohort, we 
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measured whether or not the rats developed a Conditioned Place Preference (CPP) to a sub-
threshold dosage of cocaine (7.5mg/kg).  We have previously found that this dosage is unable to 
induce CPP in most rats, but surprisingly the PreHD2 rats developed a CPP to this dosage while 
the PreLD2 rats did not.  Taken together, these results suggest a heightened sensitivity to both the 
locomotor stimulatory effects as well as the rewarding effects of cocaine use among PreHD2 rats.   
Based on these behavioral findings, we wanted to determine what neurobiological 
alterations might underlie the differential behavioral profiles of the PreHD2 and PreLD2 rats.  
This is the primary focus of this thesis.  We hypothesized that PreHD2 rats would have decreased 
dopamine release, due to increased autoreceptor inhibition of synaptic firing, while the converse 
would be true in PreLD2 rats.  We hypothesized that the heightened sensitivity to cocaine despite 
this proposed decrease in dopamine release results from compensatory up-regulation of various 
components within the dopamine pathway. To assess this, we examined multiple pre and post-
synaptic dopamine-related proteins in the Substantia Nigra (SN) and Caudate Putamen (CPu).  
The Caudate and Putamen together make up the dorsal striatum. In this nigrostriatal pathway, 
dopamine neurons in the SN project to medium spiny neurons that contain postsynaptic 
dopamine D1 or D2 receptors in CPu (Anden et al., 1964).  We examined these regions due to the 
integral role that dopamine signaling in the nigrostriatal pathway has been demonstrated to play 
in the motor-related effects of drugs of abuse, particularly in regards to locomotor activity 
(Bolanos and Nestler, 2003). The protein targets we chose to analyze include: dopamine D2 
receptor, adenosine A2A receptor, dopamine transporter (DAT), total tyrosine hydroxylase (tTH) 
and total dopamine and cAMP regulated neuronal phosphoprotein-32 (tDARPP-32.). 
In order to test potential differences in the activity states of dopamine D1 and D2 
receptors, we also analyzed the phosphorylated forms of tyrosine hydroxylase (pTH
Ser40
), 
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DARPP-32 (pDARPP-32
Thr34
).  PreHD2 and PreLD2 animals were equally divided into three 
different treatment groups: Vehicle, SKF 81297 (a selective D1 agonist), or quinpirole.  Animals 
were given their respective treatment 30 minutes prior to tissue collection in order to assess 
differential effects PreD2 levels might have on the phosphorylation states of TH and DARPP-32.  
These two proteins were chosen due to their ability to be readily phosphorylated and de-
phosphorylated and their differential synaptic localization. TH, due to its role as the rate-limiting 
enzyme in catecholamine synthesis, is primarily localized presynaptically in dopaminergic 
neurons, especially within dopamine terminal projections in the dorsal striatum (Pickel et al., 
1981). DARPP-32 is primarily localized postsynaptically in medium spiny neurons, especially in 
D1 containing neurons within the caudate and putamen (Walaas and Greengard, 1984).  
Dopamine D1 receptors are metabotropic, GS coupled receptors that enhance adenylyl 
cyclase activity (Missale et. al, 1998), which in turn causes increased cyclic adenosine 
monophosphate (cAMP) formation and enhanced protein kinase A (PKA) activity (Sibley et. al, 
1993).  Given SKF 81297’s stimulatory effects on D1, it was expected that SKF 81297 would 
enhance signaling through this pathway, leading to enhanced PKA mediated phosphorylation of 
postsynaptic substrates like DARPP-32, which has been previously demonstrated (Svenningsson 
et al., 1998).  We predicted that the PreHD2 animals would show increased phosphorylation of 
DARPP-32 relative to the PreLD2 animals due to compensatory up-regulation of stimulatory D1 
receptor levels and/or D1 mediated signaling in the face of increased presynaptic D2 sensitivity 
and the corresponding decreased dopamine release.  Due to DARPP-32’s postsynaptic 
localization in medium spiny neurons, expression was assayed only in the dorsal striatum.  It is 
unknown what effect SKF 81297 specifically might have on TH phosphorylation.  However, 
pTH
Ser40 
has been demonstrated to be enhanced following PKA phosphorylation (Bourdelles et 
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al., 1991), indicating that SKF 81297 should increase pTH levels.  Again, we predicted that the 
PreHD2 group would have higher phosphorylation ratios due to enhanced compensatory D1 
signaling.  Since TH can be found in both dopamine terminals in the CPu as well as cell bodies 
within the SN, we expected to observe this effect in both regions.  
Quinpirole treatment, via activating the dopamine D2 Gi/o  pathway, was predicted to 
inhibit the phosphorylation of both the presynaptically located TH and the postsynaptically 
localized DARPP-32, via inhibition of PKA mediated phosphorylation.  This effect was 
predicted to be especially pronounced for pTH inhibition in the PreHD2 rats, since the 
presynaptically localized pTH would be especially influenced by quinpirole activation of their 
sensitized presynaptic D2 receptors (again, this was expected in both the SN and CPu). Indeed, 
quinpirole has previously been demonstrated to reduce pTH
Ser40
 in the rat striatum (Lindgren et 
al., 2001).  Although primarily localized postsynaptically, pDARPP-32
Thr34
 was also predicted to 
decrease since the dosage of quinpirole used prior to tissue collection (1.0mg/kg) was high 
enough to target both pre and postsynaptic D2 receptors, and D2 stimulation via quinpirole has 
been shown to decrease pDARPP-32
Thr34 
(Nishi et al., 1997).  The PreHD2 animals were 
expected to have a greater decrease in pDARPP-32
Thr34
 within the dorsal striatum relative to 
PreLD2 animals due to a compensatory increase in postsynaptic D2 receptors as a result of 
decreased dopamine release. 
Methods 
Animals and Housing Conditions 
Male Sprague–Dawley rats (Charles River, Wilmington, MA) weighing 275–325 g were 
individually housed with ad libitum food and water. All experiments were conducted during the 
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light period of a (12:12) light/dark cycle in accordance with the guidelines established by the 
Institutional Animal Care and Use Committee at the University of Colorado at Boulder. 
Characterization of the quinpirole-induced locomotor behavior 
The initial locomotor response to the D2 dopamine receptor agonist, quinpirole was used 
to classify animals into groups.  Tests began at least 7 days after the arrival from the vendor and 
were conducted in darkened locomotor chambers during the light period of a (12:12) light/dark 
cycle.  All animals were first habituated to the locomotor testing apparatus for 2 hrs the day prior 
to quinpirole testing. Quinpirole-induced locomotion was assessed in a 5-hr within-session dose-
response protocol as follows: 1-hr habituation followed by hourly ascending doses of the agonist 
(0, 0.1, 0.3 and 1.0 mg/kg, s.c.). There is a biphasic effect on locomotion across the different 
doses tested. The lowest dose of quinpirole (0.1 mg/kg) generally suppresses locomotion 
compared to vehicle responding, while the higher doses (0.3 and 1.0 mg/kg, s.c.) generally 
activates locomotion. This is a prototypical quinpirole dose response, where low doses of 
quinpirole presumably stimulate D2 autoreceptors on dopamine terminals, while higher 
quinpirole doses saturate D2 autoreceptors and stimulate postsynaptic D2 receptors (Jezorski and 
White, 1989).  In order to fully characterize the D2 autoreceptor activity, locomotor suppression 
was measured using the following calculated score:  (0.1 quinpirole activity / saline activity) * 
100) - 100). A median split of this score was used to classify rats as either high presynaptic D2 
sensitivity (i.e. having high quinpirole-induced suppression) or low presynaptic D2 sensitivity 
(i.e. having little or no quinpirole-induced suppression).  For some protein analysis (see below), 
an upper/lower third split was used in addition to the median split.  Because quinpirole-induced 
locomotor activity levels varied between cohorts of animals, group classifications were made 
within each individual cohort. 
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Cocaine-induced locomotor behavior 
 In one cohort of animals (N = 39), locomotor responses were measured using a 3-hr 
within-session protocol cocaine dose-response protocol. These assessments were performed in 
darkened locomotor chambers during the light period of a (12:12) light/dark cycle. Animals were 
tested 5-7 days following initial characterization of their quinpirole sensitivity. On the test day, 
animals were habituated to the locomotor chamber for 1-hr. They were then administered hourly 
ascending doses of cocaine (5 and 15 mg/kg, i.p.).  
Cocaine place conditioning 
In another cohort of animals (N = 37), place conditioning to a sub-threshold dose of 
cocaine was measured in an unbiased 3-chamber apparatus using an unbiased 3-phase procedure. 
Testing began 7 days following the initial characterization of quinpirole sensitivity. The two 
conditioning chambers (15 cm X 25 cm X 35 cm) were distinct in wall patterns (gray vs. vertical 
white and black stripes) and floor textures (grid vs. hole). The center compartment (15 cm X 10 
cm) had white walls and a Plexiglas floor. Chambers are equipped with infrared photocells to 
detect animal position and movement in the apparatus. On the day before conditioning (pre-
conditioning), rats were allowed access to all three compartments for 20 min to test for initial 
bias. One animal was excluded from the experiment because it displayed an initial bias of 92% 
time in one compartment. Rats received three 30-min saline conditioning sessions and three 30-
min cocaine (7.5 mg/kg, i.p.) conditioning sessions. Saline conditioning occurred between 0800-
1100 hrs, while cocaine conditioning occurred between 1500-1700 hrs. In the final test session 
(post-conditioning), rats were allowed free access to the three compartments and preference was 
determined as time spent in the drug compartment minus time spent in the saline compartment 
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(conditioned place preference (CPP) score). 
Treatment and Tissue Collection  
In a different cohort of animals (N=40), animals were classified into high and low 
presynaptic D2 sensitivity groups, as previously described. Equal numbers of animals from the 
high and low presynaptic D2 sensitivity groups were subsequently placed into 3 treatment groups: 
Vehicle, SKF 81297 and Quinpirole.  Rats received their respective treatment (1.0mg/kg of SKF 
81297 or 1.0mg/kg of quinpirole). Thirty minutes following treatments, rats were rapidly 
decapitated and brains were extracted. Brains were sliced into 1.0 mm thick coronal sections 
using ice-cold razor blades and a brain matrix (Braintree Scientific Inc, Braintree, MA).  The 
brain regions of interest were collected using bilateral 12-16-gauge tissue punches.  These 
regions included the: Prefrontal Cortex, Nucleus Accumbens Core, Nucleus Accumbens Shell, 
Caudate and Putamen, Amygdala, Hippocampus, Ventral Tegmental Area, and the Substantia 
Nigra.  Tissue punches were homogenized in lysis buffer via sonication and stored at -80
O
 C 
until protein quantification and immunoblotting (see below). 
Drugs 
The D1 receptor agonist, SKF 81297 ((±)-6-Chloro-PB hydrobromide), the D2-selective 
agonist, quinpirole ((−)-quinpirole hydrochloride), and cocaine hydrochloride were obtained 
from Sigma Aldrich (St. Louis, MO).  All drugs were dissolved in sterile-filtered physiological 
(0.9%) saline. 
Immunoblotting 
Protein content was quantified using the Lowry method (BioRad, Hercules, CA, USA).  
Samples were prepared under reducing conditions in 4x Laemmli buffer and heated at 70°C for 
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10 minutes. Protein samples (15μg) were loaded onto 4–12% NuPage Bis-Tris SDS-
polyacrylamide gels (Invitrogen, Grand Island, NY) and transferred onto Immobilon-FL PVDF 
membranes (Millipore, Billerica, MA, USA). Membranes were blocked in 5% bovine serum 
albumin (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) in tris-buffered saline with 
0.1% tween (TBST) for 1 hour at room temperature. Membranes were incubated with primary 
antibody (see below) at 4°C overnight followed by 3 × 15 minute TBST washes. Membranes 
were then incubated with appropriate secondary antibodies at room temperature for 1 hour, 
washed, and detected by enhanced chemiluminescence (Super Signal West Dura and Super 
Signal West Pico, Thermo Scientific).  All images were converted to gray-scale and their 
densities quantified using ImageJ.  The following primary antibodies were obtained from Cell 
signaling and were used at concentrations of 1:1000: Tyrosine Hydroxylase (2792S), 
Phosphorylated-Tyrosine Hydroxylase (2791S), DARPP-32 (2306S), and Phosphorylated-
DARPP-32 (5393S).  The following primary antibodies were obtained from Millipore, and were 
used at concentrations of 1:2000 unless otherwise specified: Dopamine Receptor 2 (AB5084P), 
Adenosine Receptor 2A (05-717, 1:1000), Beta-Tubulin (MAB1637), and Dopamine Transporter 
(AB2231).  Secondary antibodies conjugated to horseradish peroxidase were also obtained from 
Millipore, and were dissolved in 5% BSA/TBST at concentrations from 1:10,000 to 1:50,000.  
For multiple detections of the same blot, blots were stripped using Restore Western Blot 
Stripping Buffer (Pierce, Rockford, IL) for 5-10 minutes and washed 3 × 15 minutes in TBST 
and subjected to standard immunoblotting conditions. 
Data Analysis 
 The number of animals in the behavioral experiments ranged from 37 to 40.  Cocaine-
induced locomotion was analyzed using a 2-way repeated measures ANOVA with cocaine dose 
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(5 and 15 mg/kg) and PreD2 sensitivity (PreLD2 and PreHD2) as the factors.  A preference score 
was calculated for each conditioning test (Drug-paired minus Saline-paired) and was analyzed 
using an unpaired t-test for each conditioning test.  Normalized optical densities of 
phosphorylated proteins (phospho/total protein) were calculated following immunoblotting and 
were analyzed using a 2x3 ANOVA, with D2 sensitivity (PreLD2 and PreHD2) and treatment 
(vehicle, SKF 81297, or quinpirole) as the factors.  . All non-phosphorylated proteins were 
analyzed with an unpaired t-test between PreLD2 and PreHD2.  Additionally, both a median and 
an upper/lower third split were analyzed for the non-phosphorylated proteins.  In all cases, 
significant main effects and interactions were followed up by post hoc tests.  Statistical 
significance was set to p < 0.05 for all tests.  
 
 Results 
1. PreD2 receptor sensitivity predicts cocaine-induced locomotor activity and reward 
 We utilized locomotor suppression to a 0.1mg/kg dose of quinpirole to characterize rats 
as either PreHD2 or PreLD2, with PreHD2 demonstrating the greatest suppression and PreLD2 
demonstrating little to no locomotor suppression (Figure 1a).  Because PreD2 receptor sensitivity 
has been associated with cocaine responsiveness, we wanted to examine whether our PreD2 
groups differed on cocaine-induced behaviors.  We tested whether there was a group difference 
in the locomotor activating effects of a low (5 mg/kg) and high (15 mg/kg) dose of cocaine. We 
observed a significant main effect of both dosage (F1,35= 105.1, p<0.0001) and PreD2 sensitivity 
(F1,35=6.446, p<0.05).  Post hoc testing revealed that PreHD2 animals had significantly increased 
locomotion relative to PreLD2 animals at the 15 mg/kg dose (t=1.521, p<0.05).  This suggests 
that animals characterized with high D2 autoreceptor sensitivity are also more sensitive to the 
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acute locomotor stimulating effects of cocaine.
 
Figure 1: PreD2 sensitivity increases locomotor response to high dose of cocaine. (a) This 
scatterplot was made by performing a median split of the locomotor suppression observed after 
treatment with 0.1 mg/kg quinpirole. Scores were generated by calculating a % baseline (saline-
induced activity). (b) Locomotor response to 2 doses (5mg/kg and 15 mg/kg) of cocaine as 
measured by beam breaks.   After one hour of habituation, animals were given a 5mg/kg dose 
and their locomotor activity measured for one hour.  After the hour elapsed, a second dose of 15 
mg/kg cocaine was administered and locomotor activity was again assessed.  Statistical analysis 
revealed no significant interaction between dose and PreD2.  However, significant main effects 
of both dosage and PreD2 sensitivity occurred. (* indicates significant difference between PreD2 
groups, p < 0.05)  Scatterplots of PreD2 sensitivity and cocaine-induced locomotion were used to 
determine the relationship between these two variables. Linear regression of (c) 5mg/kg cocaine 
and (d) 15 mg/kg revealed a significant inverse relationship with PreD2 sensitivity and 5 mg/kg 
cocaine-induced activity. 
 
We next wanted to assess whether the PreD2 groups also differed in the rewarding 
properties of cocaine using cocaine-induced place conditioning.  Following conditioning to a 
sub-threshold (7.5mg/kg) dosage of cocaine, PreHD2 animals developed a significant preference 
for the cocaine-paired side of the chamber during a post-conditioning test (t33 = 2.090, p<0.05), 
while PreLD2 animals did not (Fig. 2).  Since PreHD2 animals were able to develop a place 
preference to a sub-threshold dosage of cocaine that is normally insufficient to induce 
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conditioning, these results indicate an enhanced sensitivity to the rewarding effects of cocaine 
with enhanced PreD2 sensitivity. 
 
Figure 2: PreHD2 but not PreLD2 animals developed a CPP to a sub-threshold 
dosage of cocaine.  Animals were assessed for cocaine-induced CPP.  Preference score was 
obtained via subtracting time spent in the saline-paired compartment from time spent in the 
cocaine-paired compartment. PreHD2 animals displayed a preference for the cocaine-paired side 
compared to the PreLD2 animals on the post-conditioning test (t33 = 2.090, p<0.05).  In order to 
assess neurobiological correlates of these different behavioral profiles, a separate cohort of 
animals were divided into three treatment groups: Vehicle, SKF 81297, and quinpirole that were 
balanced for PreHD2 and PreLD2. 
 
2. Characterizing the neurobiological differences in PreD2 sensitivity groups 
In order to assess neurobiological correlates of these different behavioral profiles, a 
separate cohort of animals were characterized for PreD2 receptor sensitivity as previously 
described (Figure 3). We assessed activity-dependent proteins (i.e. phosphorylated proteins) 
following a challenge of Vehicle, SKF 81297, or quinpirole. Treatment groups were balanced 
among the animals characterized as PreHD2 and PreLD2 (Fig. 3b).  The expression of proteins 
not thought to be activity-dependent was analyzed by collapsing across treatment groups and 
using a median split (Fig. 3a) and upper/lower thirds split (data not shown) of their PreD2 
receptor sensitivity.  
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Figure 3: Characterization of PreD2 sensitivity prior to treatments and tissue collection.  (a) 
Scatterplot illustrating the median split of the locomotor suppression observed after treatment 
with 0.1 mg/kg quinpirole. (b) Scatterplot of locomotor response to 0.1mg/kg quinpirole, animals 
were placed into three treatment groups (Vehicle, SKF 81297, and Quinpirole) balanced for 
PreHD2 and PreLD2. 
 
3. Caudate Putamen Protein Expression  
a. Receptor Protein Expression 
We first examined the expression of dopamine D2 receptor and adenosine A2A receptor, 
due to their postsynaptic co-localization on medium spiny neurons within the CPu and their 
antagonistic intracellular effects on one another’s actions (Svenningson et al., 1999; Ferre et al., 
2008).  A median split of PreD2 sensitivity (Fig. 4a) revealed a trend towards decreased A2A 
receptor expression in PreHD2 animals (t36 = 1.787, p = 0.0824).  Analyzing upper and lower 
thirds of PreD2 sensitivity (Fig. 4b) revealed a significant difference between the PreD2 
sensitivity groups (t22 = 3.186, p< 0.01).   
Analysis of the dopamine D2 receptor, also revealed a trend when a median split of PreD2 
sensitivity (Fig. 4c) was utilized (t36 = 1.585, p = 0.1218).  However, when the upper and lower 
thirds strategy of PreD2 sensitivity (Fig. 4d) was used, the trend became much weaker (t23= 
0.9646, p=0.3448).  
-100
0
100
200
300
400
%
 B
a
s
e
li
n
e
L
o
c
o
m
o
to
r 
A
c
ti
v
it
y
V
eh
ic
le
S
K
F 
81
29
7
Q
ui
np
iro
le
-100
0
100
200
300
400
PreHD2
PreLD2
%
 B
a
s
e
li
n
e
L
o
c
o
m
o
to
r 
A
c
ti
v
it
y
a b
Schreiner 19 
 
Figure 4: PreHD2 animals had significantly lower Adenosine A2A receptor expression in the 
CPu. (a) Protein expression of A2A receptor measured via optical density of A2A normalized to -
tubulin optical density. A median split of PreLD2/PreHD2 revealed a trend towards decreased 
A2A receptor expression in PreHD2 animals. (b) Utilizing an upper/lower thirds split of PreD2 
sensitivity revealed a significantly decreased A2A receptor expression (*).  (c) Protein expression 
of D2, measured via normalizing D2 optical density to tubulin. Median split of PreD2 
sensitivity revealed a trend towards decreased D2 receptor expression. (d) An upper/lower third 
split of PreD2 sensitivity found no significant change in D2 expression.   Representative bands of 
each protein are shown to the right of the graphs, H indicating a PreHD2 animal and L indicating 
a PreLD2 animal.    
 
b. Presynaptic Protein Expression 
 In order to assess the effects PreD2 sensitivity on presynaptic protein expression, we 
assayed both Dopamine Transporter (DAT) and Tyrosine Hydroxylase (TH), which are localized 
in the presynaptic terminals of dopamine neurons in the CPU (Ciliax et al., 1995; Pickel et al., 
1981).  Both a median split (Fig. 5a) of PreD2 sensitivity (t35 = 1.588, p=0.1214) and an 
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upper/lower third split (Fig. 5b) of PreD2 sensitivity (t22 =1.660, p=0.1111) revealed a trend 
towards decreased DAT expression among PreHD2 animals although neither met our criteria for 
significance. 
 There was no significant difference in TH expression between PreLD2 and PreHD2 
animals for either a median (t36=0.03807, p=0.9698) or upper/lower thirds (t24= 0.3251, 
p=0.7479) split of PreD2 sensitivity (data not shown). 
Figure 5: Dopamine Transporter expression is decreased in PreHD2 animals. (a)  Protein 
expression of DAT as measured by optical density.  A median split of PreD2 sensitivity revealed 
a trend towards decreased DAT expression. (b) An upper/lower third split of PreD2 sensitivity 
also showed a trend towards decreased DAT expression.  Representative bands are shown to the 
right of the graphs, H indicating a PreHD2 animal and L indicating a PreLD2 animal. 
 
c. Postsynaptic Protein Expression 
In order to determine the effects of PreD2 sensitivity on postsynaptic protein expression, 
we examined DARPP-32, which is localized within medium spiny neurons within the CPu 
(Walaas and Greengard, 1984).  We found that there was a trend towards decreased DARPP-32 
expression in PreHD2 animals when utilizing both a median split (Fig. 6a) of PreD2 sensitivity 
(t34 = 1.575, p=0.1246) and an upper/lower thirds split (Fig. 6b) of PreD2 sensitivity (t21 = 1.914, 
p=0.0694), although neither met our criteria for significance. 
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Figure 6: DARPP-32 expression is decreased in PreHD2 animals. (a) DARPP-32 protein 
expression, measured via optical density normalized to -tubulin.  A median split of PreD2 
sensitivity revealed a trend towards decreased DARPP-32 expression in PreHD2 animals. (b) An 
upper/lower thirds split of PreD2 sensitivity also saw a trend towards decreased DARPP-32 
expression in PreHD2 animals.  Representative bands for each protein are shown to the right of 
the graphs, with H indicating a PreHD2 animal and L indicating a PreLD2 animal. 
 
4. Substantia Nigra Protein Expression 
Within the SN, dopamine D2 autoreceptors tend to be localized on the somas of dopamine 
neurons.  Statistical analysis of D2 expression revealed no significant difference between PreHD2 
and PreLD2 animals when either a median (t32= 0.4978, p=0.6220) or an upper/lower thirds 
(t22=1.179, p=0.2510) split was used (data not shown). 
  DAT and TH are also localized within the cell bodies of SN dopamine neurons (Ciliax et 
al., 1995; Pickel et al., 1981).  Although a median split (Fig. 7a) of PreD2 sensitivity did not 
demonstrate any significant difference in expression (t31=1.265,p=0.2153) an upper/lower thirds 
split (Fig. 7b) revealed a trend towards a significant decrease of DAT expression in PreHD2 
animals (t20 = 1.816, p=0.0844).  
For TH, both a median split (Fig.7c) (t31 = 1.734, p=0.0928) and an upper/lower thirds 
split (Fig. 7d) (t21 = 1.629, p=0.1182) of PreD2 sensitivity demonstrated a trend towards a 
significant decrease in TH expression among PreHD2 animals relative to PreLD2 animals. 
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Figure 7: PreHD2 animals had decreased expression of both Dopamine Transporter and 
Tyrosine Hydroxylase.  (a) Protein expression as measured via optical density normalized to -
tubulin. Median split of PreD2 sensitivity revealed no significant difference between PreHD2 and 
PreLD2. (b) Upper/lower third split of PreD2 revealed a trend towards a significant decrease of 
DAT expression in PreHD2.  (c)  Median split of PreD2 revealed a trend towards decreased TH 
expression. (d) This trend continued utilizing an upper/lower third split of PreD2 sensitivity.  
Representative bands are shown to the right of the graphs, H indicating a PreHD2 animal and L 
indicating a PreLD2 animal. 
 
5. Activity Dependent Changes in Phosphoproteins 
a. Phosphoprotein expression in the Caudate Putamen 
We first assessed the phosphorylation of the presynaptic protein TH. Phosphorylation of 
TH increases the kinetics of enzymatic activity and reflects alterations in presynaptic terminal 
activity in the CPU.  Analysis of the raw optical densities of pTH
Ser40/
/tTH ratios within the CPu 
(Fig. 8a) saw no significant interaction between treatment and PreD2 sensitivity (F2,44=1.814, 
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p=0.1749).  A 2x3 ANOVA found significant main effects of both treatment (F2,44 = 5.719, 
p<0.01) and PreD2 sensitivity (F1,44 = 5.855, p<0.05).  Normalizing the pTH
Ser40
/tTH ratios (Fig. 
8b) to control (i.e., PreHD2 and PreLD2 animals were normalized to their respective vehicle 
treatment) found no significant interaction (F2,44 = 1.452, p= 0.2450), or significant main effect 
of PreD2 sensitivity (F1.44 = 1.181, p= 0.2831), but only a significant main effect of treatment 
(F2,44 = 4.300, p<0.05).   
We next examined the phosphorylation ratios of DARPP-32 (Fig. 9a), which is localized 
in medium spiny neurons in the CPu. 2x3 ANOVA revealed no significant interaction (F2,42 = 
1.448, p=0.2464) and no significant effect of PreD2 sensitivity (F1,42 = 2.098, p=0.1549) while 
treatment did have a significant effect (F2,42 = 4.733,p<0.05) on pDARPP-32
Thr34
/tDARPP-32. 
When the raw phosphorylation ratios were normalized to control (Fig. 9b), there was again no 
significant interaction (F2,42 = 0.8465, p= 0.4361) and no significant effect of PreD2 sensitivity 
(F1,42 = 0.1916, p=0.6638).  There was only a significant main effect of treatment (F2,42 = 3.748, 
p<0.05) on pDARPP-32
Thr34
 phosphorylation.   
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Figure 8 : SFK 81297 increased pTH
Ser40
 in PreLD2 but not PreHD2 rats.  (a) Raw optical 
density of pTH/tTH ratios within the CPu.   These values were obtained by dividing the optical 
density of pTH
Ser40
/tTH. No significant interaction was found between treatment and PreD2 
sensitivity.  Significant main effects of both treatment  and PreD2 sensitivity occurred.  Post hoc 
testing of treatment effect found an overall significant variation (F=3.812,p<0.05).  Bonferroni’s 
comparisons found that SKF 81297 significantly increased the pTH
Ser40/
/tTH ratios relative to 
vehicle (*t=2.740, p<0.05) but found no significant difference between vehicle and quinpirole 
(t=1.331, p>0.05) or SKF 81297 and quinpirole (t=1.297, p>0.05).  However, contrary to the 
ANOVA analysis, post hoc tests of PreD2 sensitivity revealed no significant effect (t4=1.246, 
p=0.2806).  Additional post hoc testing (Bonferroni’s comparisons) revealed that SKF 81297 had 
a significant effect (t =2.738, p<0.05) on increasing pTH
Ser40
/tTH ratios in PreLD2 but not 
PreHD2 animals.  (b) pTH/tTH values normalized to vehicle.  The average vehicle treatment 
pTH
Ser40
/tTH was placed at an effect size of 100% (note, the PreHD2 and PreLD2 groups had 
different actual values that represented 100% of an effect).  The averages of the SKF 81297 and 
quinpirole treatments were then compared to this control value.  There was no significant 
interaction, or a signifiant effect of PreD2 sensitivity.  There was a significant main effect of 
treatment.  Post hoc testing of treatment using a one-way ANOVA found significant variation 
amongst the treatment groups (F=3.419, p<0.05).  Bonferroni’s comparisons found that SKF 
81297 was significantly increased relative to Vehicle (*t=2.609, p<0.05), while neither Vehicle 
and quinpirole (t=1.124,p>0.05) nor SKF 81297 and quinpirole (t=1.362, p>0.05) differed 
significantly.  Representative bands are shown underneath the graphs. 
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Figure 9: DARPP-32 phosphorylation was unaffected by PreD2 sensitivity. (a) Protein 
expression as measured via optical density of pDARPP-32
Thr34
/tDARPP-32.  A significant main 
effect of treatment occurred.  Post hoc testing revealed that SKF 81297 increased pDARPP-
32
Thr34 
relative to both vehicle (t2,45=2.573, p<0.05) and quinpirole (*t2,45 = 2.773, p<0.05), 
though there was no significant difference between vehicle and quinpirole treatments 
(t=2.773,p>0.05).  (b) pDARPP
Thr34
/tDARPP-32 values normalized to vehicle treatment.  No 
significant interaction or effect of PreD2 sensitivity was found.  A significant main effect of 
treatment was found.  Post hoc testing revealed that SKF 81927 increased phosphorylation 
relative to quinpirole (*t2,45= 2.531, p<0.05), but neither Vehicle and quinpirole 
(t=0.6680,p>0.05) nor Vehicle and SKF 81297 (t=2.234,p>0.05) were significantly different.  
Representative bands are shown below the graphs. 
 
b. Phosphoprotein expression in the Substantia Nigra 
 Due to its localization in medium spiny neurons within the striatum, we did not examine 
DARPP-32 phosphorylation within the SN.  Analysis of the phosphorylation of TH revealed no 
significant interaction (F2,29= 1.496, p=0.2408)  or main effect of either treatment (F2,29 = 0.9963, 
p=0.3815) or PreD2 sensitivity (F1,29 = 2.970, p=0.3815) on the raw optical density of 
pTH
Ser40
/tTH values.  When these values were normalized to control, there was a significant 
main effect of both treatment (F2,29 = 3.625, p<0.05) and PreD2 sensitivity (F1,29 = 9.203, p<0.01). 
There was also a significant interaction between the two (F2,29 = 3.948, p<0.05).  
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Figure 10: Quinpirole significantly increased pTH
Ser40
 in PreLD2 but not PreHD2 animals. 
(a) Protein expression as measured via optical density of pTH
Ser40
/tTH, no significant effects 
occurred. (b) pTH
Ser40
/tTH values normalized to control.  A significant main effect of both 
treatment and PreD2 sensitivity occurred.  A one-way ANOVA of treatment effect found a 
significant variation (F=3.308, p<0.05) amongst the treatments, but Bonferroni’s comparisons 
found no significant difference between Vehicle and SKF 81297 (t=0.7847,p>0.05), Vehicle and 
quinpirole (t=2.475,p>0.05) or SKF 81297 and quinpirole (t=1.693,p>0.05).  Post hoc testing of 
PreD2 sensitivity found no significant difference between PreHD2 and PreLD2 (t4=1.597, 
p=0.1856).  Additionally, there was a significant interaction between treatment and PreD2 
sensitivity.  Post hoc testing revealed that quinpirole significantly increased pTH
Ser40
 in PreLD2 
but not PreHD2 animals (*t=4.213, p<.001).  Representative bands are shown beneath the graphs.  
 
Discussion 
We used a novel animal model of presynaptic D2 sensitivity to screen for differential 
behavioral responses to cocaine.  D2 autoreceptors tend to decrease the firing rate of dopamine 
neurons, decrease dopamine synthesis, and decrease dopamine release (Beaulieu and 
Gainetdinov, 2011).  Because of this, we predicted that  animals with high presynaptic D2 
autoreceptor sensitivity (PreHD2) would have increased inhibition of dopamine signaling relative 
to animals with low presynaptic D2 autoreceptor sensitivity (PreLD2).  Our behavioral data 
demonstrated that, despite increased D2-mediated inhibitory signaling, PreHD2 animals actually 
displayed increased sensitivity to both the locomotor stimulating and rewarding effects of 
cocaine.  To account for their behavioral sensitivity to cocaine in the face of decreased dopamine 
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signaling, we hypothesized that there must be alterations in components of the dopamine 
signaling pathway such as compensatory up-regulation of postsynaptic receptor signaling that 
rendered the PreHD2 rats more sensitive to cocaine.   
In order to determine whether or not this prediction was accurate, we assessed expression 
of several dopamine associated proteins within the nigrostriatal pathway.  The SN is a midbrain 
region where dopamine cell bodies exist and send projections to the CPu (dorsal striatum) 
(Anden et al., 1964).  In the CPu, dopamine neurons synapse onto medium spiny neurons, which 
comprise the majority of the striatal cells.  Additionally, dopamine D1 receptor  containing MSNs 
from the dorsal striatum send reciprocal projections back to the SN as a feedback mechanism 
(the striatonigral pathway).  The nigrostriatal pathway has been demonstrated to be crucial for 
normal motor behaviors, motor learning, and has also been strongly implicated in the motor-
related effects of drugs of abuse (Bolanos and Nestler, 2003).   For instance, it has been found to 
be crucial for the locomotor activating effects of psychostimulants (Creese and Iverson, 1975).  
Given that our model used locomotor activity to characterize PreD2 sensitivity, and furthermore, 
that we saw increased cocaine-induced locomotor activity in PreHD2 rats, the nigrostriatal 
pathway was a clear choice.  Therefore, we chose to examine protein expression in dopamine 
neurons of the SN and their primary projection region, the dorsal striatum, to assess them for 
neurobiological alterations that might underlie the observed behavioral differences. 
 Within the SN, we found trends towards decreased expression of both DAT and TH, 
both of which could be linked to the heightened inhibitory D2 signaling in PreHD2 animals.  
Within the dorsal striatum, we found significantly decreased adenosine A2A receptor expression 
that might correspond with PreHD2 animals having less antagonistic signaling on postsynaptic D2 
receptor signaling (see below).  Also within the dorsal striatum, we found trends toward 
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decreased D2, DAT, and DARPP-32 expression.  We also examined activity-dependent changes 
in phosphoprotein regulation between PreHD2 and PreLD2 animals in an attempt to identify 
functional neurobiological differences between these groups.   In the dorsal striatum, we found 
that the D1 agonist, SKF 81297, increased pTH
Ser40
 in PreLD2 but not PreHD2 animals.  For 
pDARPP-32
Thr34
, we found no difference between PreHD2 and PreLD2, though SKF 81297 
increases pDARPP-32
Thr34 
in both groups.  In the SN, we found a significant interaction between 
PreD2 sensitivity and treatment, with the D2 agonist, quinpirole significantly increasing pTH
Ser40 
in PreLD2 but not PreHD2 rats. 
Receptor Protein Expression 
Adenosine A2A receptors tend to be co-localized with postsynaptic dopamine D2 receptors 
in MSNs of the dorsal striatum.  We found that adenosine A2A receptor expression was 
significantly decreased in PreHD2 animals within the dorsal striatum. Stimulation of A2A 
receptors opposes D2 receptor signaling by activating stimulatory G-proteins that enhance 
adenylyl cyclase activity and cAMP formation (Svenningson et. al, 1999).  In addition to 
antagonizing the effects on intracellular signaling cascades, A2A receptors have also been found 
to form inhibitory heteromeric complexes with D2 receptors that decrease D2 receptor affinity for 
dopamine (Ferre et. al, 2008).  The significantly lower levels of A2A receptors found in the dorsal 
striatum of the PreHD2 rats could indicate that A2A is exerting less of an inhibitory effect on 
postsynaptic D2 signaling.  This fits our framework.  This decreased A2A-mediated inhibition of 
D2 would effectively up-regulate postsynaptic D2 signaling to be more responsive to dopamine.  
This could account for the observed behavioral sensitivity to cocaine.  In support of this, it has 
been shown that the selective A2A agonist CGS 21680 attenuates the locomotor activation of 
acute cocaine and also reduces the sensitization of locomotor activity following prolonged 
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cocaine injections (Filip et al., 2006).  Furthermore, CGS 21680 has been shown to both reduce 
reinstatement of cocaine seeking (Bachtell and Self, 2009) and to inhibit acquisition of self-
administration behavior (Knapp et al., 2001).  The decreased expression of A2A in PreHD2 rats 
could thus confer a vulnerability to addiction.   Follow-up studies on the propensity of PreHD2 
rats to acquire self-administration or reinstate following extinction training would be needed to 
determine whether or not this holds true in our model.   Since our results are correlative, it is not 
possible to discern what relationship exists between PreD2 sensitivity and A2A expression.  PreD2 
sensitivity could be causing decreased A2A expression, or it may be that the decreased A2A 
expression among PreHD2 rats causes them to be more sensitive to D2 stimulation as a result of 
decreased antagonistic signaling.  Alternatively, there could be some external factor that 
influences PreD2 sensitivity and/or A2A expression. 
There was a trend towards decreased dopamine D2 receptor expression within the CPu 
among PreHD2 animals, but no change in expression within the SN.  This result is intriguing.  
One possible reason for PreHD2 animals to have appeared to be more sensitive to 
presynaptically-targeted quinpirole was simply the expression of greater numbers of presynaptic 
D2 receptors.  Unfortunately, our method of assaying protein expression cannot distinguish 
between pre and postsynaptic expression.  It is possible that, while total D2 levels are either 
decreased in PreHD2 animals (the CPu) or unaffected (the SN), presynaptic D2 expression is 
preferentially increased.  The D2 receptor exists in two different isoforms: D2S (short) and D2L 
(long).  D2S receptors are a truncated isoform of D2 receptors that is localized presynaptically, 
and have higher affinity for dopamine, while D2L receptors have a lower affinity for dopamine 
and are localized postsynaptically (Lindgren et al., 2003).  Further studies utilizing antibodies 
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specific to the two isoforms could elucidate what relationship, if any, exists between PreD2 
sensitivity and pre and postsynaptic D2 expression.  
The observed decrease or lack of change in D2 receptor expression coupled with a 
seemingly paradoxical increase in sensitivity to cocaine may seem counter-intuitive.  However, 
this finding is supported by the literature.  As previously mentioned, Volkow and colleagues 
(1999) found increased subjective drug liking correlated with decreased D2 receptor expression, 
while another study found decreased striatal D2 receptors in drug addicts (Volkow et al., 2009).  
Thus, decreased D2 receptor densities may be a vulnerability factor, a consequence of chronic 
drug use, or both.  Interestingly, when mice were given a chronic, binge-like dosage of cocaine, 
they had decreased D2 expression in the striatum but an increase in D2-stimulated G protein 
activity (Bailey et al., 2008).  This coincides with our prediction of the effects of PreHD2 
sensitivity, whereby decreased dopamine release leads to compensatory up-regulation of 
dopamine signaling pathways. 
 Another possible explanation for this seeming dichotomy is that the D2 receptor is known 
to exist in two different affinity states: D2
High 
and D2
Low
 (Seeman et al., 2006), and the D2
High 
state 
is known to be increased following cocaine self-administration without any change in total D2 
receptor expression (Briand et al., 2008).  Our model of PreHD2 sensitivity could thus indicate 
that these presynaptic D2 receptors predominantly exist in a high affinity state, accounting for 
their observed sensitivity to the D2 agonist quinpirole. 
Presynaptic Protein Expression 
DAT is localized to dopamine neurons, where it can be localized at either the cell body 
(in the SN) or at axon terminals (in the CPu).  DAT is responsible for re-uptake and recycling of 
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dopamine from the synapse.  We found a trend towards a significant decrease in expression of 
DAT in the PreHD2 animals in both the SN and the CPu.  These results concur with our proposed 
PreD2 sensitivity framework.  Stimulation of both somatodendritic and presynaptic D2  
autoreceptors has been demonstrated to reduce dopamine cell firing, with presynaptic D2 
autoreceptors being especially potent at inhibiting release (Cragg and Greenfield, 1997).  Thus, 
the PreHD2 animals should have reduced cell firing, and reduced dopamine release relative to 
PreLD2 animals.  This reduced cell firing and dopamine release would mean there is less need 
for dopamine re-uptake from the synapse, and hence, less need for DAT to be expressed at high 
levels.  DAT knockout mice display basal hyperlocomotion, presumably because their inability 
to re-uptake dopamine leads to the prolonged presence of synaptic dopamine; however, since 
they lack DAT for cocaine to act on, they are unresponsive to cocaine-induced locomotion (Sora 
et al., 1998).  The decreased DAT expression in PreHD2 rats could indicate that they are less 
efficient at re-uptake of dopamine, which could account for their enhanced behavioral sensitivity 
to cocaine.  The flood of dopamine caused by cocaine would not be able to be cleared as 
efficiently in PreHD2 rats due to their decreased DAT expression, meaning its effects would be 
more pronounced and perhaps more persistent.  In support of this, Nelson et al. (2009) found 
decreased dopamine binding to DAT and increased extracellular dopamine in rats that had a high 
locomotor response to cocaine relative to rats that had a low locomotor response to cocaine.  
Like DAT, TH is also localized to dopamine cell bodies within the SN and axon 
terminals in the CPu, where it functions as the rate-limiting enzyme of catecholamine synthesis.  
We found a trend towards decreased total TH (tTH) expression in the SN among PreHD2 rats, but 
no change in expression in the CPu.  D2 autoreceptors have been found to decrease dopamine 
synthesis when localized either somatodendritically or presynaptically (Wolf and Roth, 1990).  
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The decreased tTH expression in the SN fits our framework.  The sensitized autoreceptors of 
PreHD2 animals would lead to greater inhibition of synthesis.  It is somewhat puzzling that we 
did not see a corresponding decrease in tTH expression in the CPu.  One explanation is that 
dopamine can negatively feedback onto TH to prevent it from synthesizing more catecholamines 
(Wolf and Roth, 1990).  It may be that the decreased amount of dopamine release leads to a 
build-up of dopamine at the axon terminal, causing inhibition of TH.  Thus, perhaps presynaptic 
tTH expression is unchanged while its function is inhibited. 
Postsynaptic Proteins 
Though not significant, a trend of decreased total DARPP-32 (tDARPP-32) was observed 
among the upper third of PreHD2 animals within the CPu.  This result is interesting.  We 
predicted a compensatory increase in the D1 signaling cascade to offset the heightened D2 
autoreceptor sensitivity, which should in turn lead to increased tDARRP-32 expression.  The fact 
that we observed decreased tDARPP-32 expression could indicate that, rather than (or perhaps in 
addition to) increased D1 signaling, PreD2 sensitivity causes increased compensatory postsynaptic 
D2 signaling, since D2 signaling is known to inhibit DARPP-32 (Fienberg et al., 1999). This 
could be a result of the aforementioned decrease in antagonistic A2A signaling (see above), or 
some other factor. 
This result slightly conflicts with our behavioral data.  In contrast to our CPP data, 
DARPP-32 knockout mice have reduced sensitivity to the rewarding effects of cocaine 
(Zachariou et al., 2002).  However, the rewarding effects of cocaine appear to be regulated 
primarily by the ventral striatum (Koob and Volkow, 2010), which we did not assay for protein 
expression.  The effects on acute cocaine-induced locomotor activity are less clear and appear to 
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be dose-dependent.  Using a 20 mg/kg dose of cocaine, both Hiroi et al. (1999) and Fienberg et 
al. (1998) found no difference in cocaine-induced locomotor activity between wild-type and 
DARPP-32 knockout mice.  However, Fienberg et al. (1998) found an attenuated locomotor 
response to a 10mg/kg dosage.  Interestingly, Hiroi et al. (1999) also found that DARPP-32 
knockout mice had enhanced locomotor sensitization to repeated cocaine treatments.  Thus, it 
could be that the reduced tDARPP-32 among PreHD2 animals indicates that they have some 
basally heightened sensitivity to the locomotor stimulating effects of cocaine.  Of course, 
PreHD2 rats might also have other neuroadaptations within their dopamine signaling that 
outweigh the effects DARPP-32 might have on locomotor activity. 
Presynaptic Phosphoprotein Regulation 
We expected SKF 81297 to increase (Bourdelles et al., 1991), and quinpirole to decrease 
(Lindgren et al., 2001) pTH
Ser40
 within the CPu.  PreLD2 but not PreHD2 animals saw a 
drastically increased pTH
Ser40
/tTH ratio when treated with SKF 81297, while quinpirole had no 
effect.  Although SKF 81297 increased pTH when collapsing across groups, PreLD2 animals had 
a much more robust increase of pTH than did PreHD2 animals, which ran counter to our 
prediction.  We predicted that  PreLD2 animals should have relatively higher basal acitivty in 
their dopamine signaling, leading to compensatory down-regulation and thus, decreased 
responsiveness to the D1 agonist SKF 81297 relative to PreHD2 animals.  A possible explanation 
for this unexpected result is that  the increased amount of dopamine signaling and release in 
PreLD2 animals caused an up-regulation of dopamine synthesis.  The increased release of 
dopamine would lead to less dopamine present presynaptically and hence, less negative feedback 
on TH.  Therefore, PreLD2 animals could actually be more responsive to SKF 81297 than 
PreHD2 animals, who might have greater negative feedback as a result of greater presynaptic 
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dopamine stores.  Additionally, it is important to note that our treatments were given 
systemically, meaning SKF 81297 and quinpirole could be acting on different brain regions that 
in turn act indirectly on the nigrostriatal pathway to regulate pTH
Ser40
.  
In the SN, we again expected SKF 81297 to increase and quinpirole to decrease pTH
Ser40
. 
Our results were not what we expected, and they are in opposition to what has been 
demonstrated in the literature (Bourdelles et al., 1991; Lindgren et al., 2001).  SKF 81297 had no 
effect while quinpirole actually increased pTH
Ser40
 in PreLD2 but not PreHD2 rats.   Though not 
significant (see Fig. 10a), the PreHD2 rats appear to have a basally increased ratio of pTH/tTH in 
the SN which was unaffected by any treatment.  As mentioned previously, we found that tTH 
expression trended towards decreased expression in PreHD2 animals within the SN.  Because this 
result was not significant, we still normalized the pTH
Ser40
 to tTH, but this trend towards 
decreased tTH could be masking decreases in pTH
Ser40
, making it appear as though PreHD2 
animals have a high basal pTH
Ser40
/tTH ratio.   It is also possible that the increased basal pTH
Ser40
 
in the PreHD2 rats could be as a result of increased compensatory D1 signaling.  However, it is 
puzzling that neither SKF 81297 nor quinpirole appeared to have an effect on TH 
phosphorylation  in PreHD2 rats.  It could be that the pTH
Ser40
/tTH ratio has already reached 
some ceiling, preventing SKF 81297 from increasing it any further, but that would not account 
for quinpirole’s inability to decrease it.  Quinpirole increased pTHSer40/tTH in PreLD2 rats 
compared to PreHD2 rats.  The fact that quinpirole paradoxically increased phosphorylation is 
not supported by the literature.  Another possible confound is again the systemic method of 
administration.  Quinpirole could be inhibiting an inhibitor.  That is, inhibition of D2 containing 
GABA neurons may remove their inhibition of dopamine neurons, leading to increased pTH
Ser40
/   
TH.  It seems likely that both the decreased tTH in the SN and the fact that quinpirole was 
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administered systemically influenced our results, and impaired our ability to ascertain accurate 
measurements of pTH
Ser40
.  
Postsynaptic Phosphoprotein Regulation 
  In the CPu, we expected SKF 81297 to increase and quinpirole to decrease       
pDARPP-32
Thr34
, as this has been previously demonstrated in the literature (Nishi et al., 1997).  
As expected, we found that SFK 81297 increased pDARPP-32
Thr34
 within the CPu; however, 
there was no difference observed between PreHD2 and PreLD2 animals and quinpirole had no 
effect on pDARPP-32
Thr34
.  The fact that we also found a trend towards decreased tDARPP-32 in 
the CPu of PreHD2 animals confounds this result.  The effect was not significant, so again, we 
still normalized pDARPP-32
Thr34
 to tDARPP-32, but it could be that the decreased tDARPP-32 is 
masking a decrease in pDARPP-32
Thr34
, leading to the apparent lack of difference between the 
two groups.  The lack of a quinpirole effect may relate to quinpirole-induced dephosphorylation 
of pDARPP-32
Thr34
, which is Ca
2+
 and calcineurin dependent (Nishi et al., 1999).  D2 stimulation 
is known to reduce L-type Ca
2+
 currents via G (Hernandez-Lopez et al., 2000), hence PreHD2 
animals might have decreased basal availability of Ca
2+  
 (due to their sensitized D2 signaling) to 
activate calcineurin, preventing it from dephosphorylating pDARPP-32
Thr34
 even following 
direct D2 stimulation, though this would not account for the lack of effect in the PreLD2 rats.  As 
for the other phosphoproteins, it seems likely that systemic administration of our treatments 
could be influencing these results via indirect influence of other brain regions on the CPu. 
Summary 
The results of this study provide an interesting new model to study individual differences that 
may predispose an individual to addiction.  This study has found that the sensitivity of D2 
autoreceptors confers responsiveness to the behavioral effects of cocaine that correlate with 
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several alterations of dopamine signaling in the nigrostriatal pathway.  More research using this 
model should be directed in several ways:  (1) Behavioral studies to determine if PreD2 
sensitivity confers other behavioral phenotypes that predispose animals to addiction (2) 
Neurobiological studies to determine with greater specificity where the alterations are occurring 
and if other brain regions are involved and (3) Correlative studies to determine what effect other 
factors (stress, genetics/epigenetics, drug use) might have on PreD2 sensitvity. 
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